Christian Dullin

Dr. Christian Dullin

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in ACS Nano
Verified
Journal Article
Open access
BPBeatriz Pelaz
Beatriz Pelaz
CAChristoph Alexiou
Christoph Alexiou
Ramon Alvarez-PueblaRamon Alvarez-Puebla
Ramon Alvarez-Puebla
FAFrauke Alves
Frauke Alves
AAAnne M. Andrews
Anne M. Andrews
WPWolfgang Parak
Wolfgang Parak
The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic.

8 January 2015 in Blood
Verified
Journal Article
Open access
PDF file
ARAndreas Reinisch
Andreas Reinisch
NENathalie Etchart
Nathalie Etchart
DTDaniel Thomas
Daniel Thomas
NHNicole A. Hofmann
Nicole A. Hofmann
MFMargareta Fruehwirth
Margareta Fruehwirth
DSDirk Strunk
Dirk Strunk
Key Points: Epigenetics and in vivo behavior can distinguish MSCs from different sources. BM-derived MSCs form a hematopoietic niche via a vascularized cartilage intermediate.

20 January 2012 in International Endodontic Journal
Verified
Journal Article
Closed access
PDF file
TRT. Rödig
T. Rödig
THT. Hausdörfer
T. Hausdörfer
FKF. Konietschke
F. Konietschke
CDChristian Dullin
Christian Dullin
WHW. Hahn
W. Hahn
MHM. Hülsmann
M. Hülsmann

1 February 2014 in International Endodontic Journal
Verified
Journal Article
Closed access
PDF file
TRT. Rödig
T. Rödig
PRP. Reicherts
P. Reicherts
FKF. Konietschke
F. Konietschke
CDChristian Dullin
Christian Dullin
WHW. Hahn
W. Hahn
MHM. Hülsmann
M. Hülsmann

1 January 2008 in Biomaterials
Verified
Journal Article
Closed access
HSHenning Schliephake
Henning Schliephake
HWHerbert A. Weich
Herbert A. Weich
CDChristian Dullin
Christian Dullin
RGRudolf Gruber
Rudolf Gruber
SFSarah Frahse
Sarah Frahse

29 January 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
IEInes Ecke
Ines Ecke
FPFrauke Petry
Frauke Petry
ARAlbert Rosenberger
Albert Rosenberger
STSvantje Tauber
Svantje Tauber
SMSven Mönkemeyer
Sven Mönkemeyer
HHHeidi Hahn
Heidi Hahn
Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here, we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza-2′deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model. [Cancer Res 2009;69(3):887–95]